<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576914</url>
  </required_header>
  <id_info>
    <org_study_id>2006 BAI02A02[1]-01</org_study_id>
    <nct_id>NCT00576914</nct_id>
  </id_info>
  <brief_title>Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer</brief_title>
  <official_title>Adjuvant Vinorelbine Plus Cisplatin Versus Vinorelbine Plus Cisplatin Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer (Phase III Study, Randomized, Open, Multi-center)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar&#xD;
      prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with&#xD;
      completely resected IB-IIIA non-small-cell lung cancer.&#xD;
&#xD;
      The patients with completely resected stage IB to stage IIIA non-small cell lung cancer were&#xD;
      randomly assigned to the group of vinorelbine plus cisplatin plus endostar or to the group of&#xD;
      vinorelbine plus cisplatin . The primary end point was overall survival; principal secondary&#xD;
      end points were recurrence-free survival and the toxicity and safety of the regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is an open labelled, randomized, multi-center phase III clinical trail.A total of 1108&#xD;
      patients with resected stage IB to stage IIIA non-small cell lung cancer will either ether&#xD;
      the group of vinorelbine plus cisplatin plus endostar or the group of vinorelbine plus&#xD;
      cisplatin randomly. The primary end point was overall survival; principal secondary end&#xD;
      points were recurrence-free survival and the toxicity and safety of the regimens.The major&#xD;
      inclusive criteria are pathological confirmed non-small cell lung cancer after complete&#xD;
      resection and can tolerate chemotherapy safely.The tissue and blood samples will be banked&#xD;
      for further investigation. All of the enrolled patients will be followed up until death or&#xD;
      over 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>five year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence-free survival and the toxicity and safety of the regimens</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1108</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vinorelbine plus cisplatin plus recombinant human endostatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>vinorelbine plus cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human endostatin</intervention_name>
    <description>recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>endostar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer, the pathology type includes&#xD;
             squamous cell carcinoma, adenocarcinoma, large-cell carcinoma, and any mixed type of&#xD;
             the 3 types mentioned above.&#xD;
&#xD;
          -  Stage IB-IIIA non-small cell lung cancer, tumor was completely resected (The type of&#xD;
             surgery including lobectomy, left side pneumonectomy,bi-lobectomy).&#xD;
&#xD;
          -  The time from surgery to first dose of adjuvant chemotherapy are mandatory between 4-8&#xD;
             weeks.&#xD;
&#xD;
          -  No evidence of tumor relapse prior to adjuvant therapy.&#xD;
&#xD;
          -  Age 18-70, ECOG performance status 0-1.&#xD;
&#xD;
          -  Normal hematologic function.Renal function , hepatic and cardiac function will be&#xD;
             within the acceptable ranges as following:serum bilirubin, AST and ALT levels below&#xD;
             1.5 times of normal value.&#xD;
&#xD;
          -  No history of chemotherapy or radiotherapy;&#xD;
&#xD;
          -  The patient should have well compliance for chemotherapy and follow up.Informed&#xD;
             consent should be obtained before treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The histological or cytological documents do not match the inclusion criteria.&#xD;
&#xD;
          -  Right side pneumonectomy or any kind of incompletely resected surgery.&#xD;
&#xD;
          -  The recruitment time are beyond 8 weeks from surgery.&#xD;
&#xD;
          -  Any concurrent acute or chronic systemic diseases or psychiatric diseases, which might&#xD;
             both increase the risks of the research itself or the medical therapy and influence&#xD;
             the research results analysis. The researchers can make a judge for the following&#xD;
             conditions to tell whether they are fit for this research:Uncontrolled high blood&#xD;
             pressure, unstable angina , myocardial infarction , uncontrolled arrhythmia,or&#xD;
             congestive heart failure with clinical symptoms within 12 weeks before&#xD;
             randomization.Evidence of anemia from electrocardiographic manifestation or heart&#xD;
             valve disease with confirmed clinical diagnosis.Clinically significant active&#xD;
             infection state due to bacteria, virus and fungi invasion. Patients with grade II&#xD;
             arrhythmia, grade II myocardial anemia, grade II abnormal cardiac troponin T, grade II&#xD;
             high blood pressure or left ventricle ejection fraction (LVEF) less than 50 percent&#xD;
             according to CTC 3.0 are not permitted to enrol the study.&#xD;
&#xD;
          -  women with pregnant or lactation.&#xD;
&#xD;
          -  Before enter the group,the patients had other malignant tumors except for non-melanoma&#xD;
             skin cancer, carcinoma in situ and cured early-stage prostate cancer.&#xD;
&#xD;
          -  With allergic constitution or possible allergic reflection to any known research&#xD;
             drugs.&#xD;
&#xD;
          -  Poor compliance.&#xD;
&#xD;
          -  Not proper for the research according to the researchers' judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie He, M.D. &amp; Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinling Liu, Bachelor</last_name>
    <phone>86-10-87788495</phone>
    <email>liuxinling1985@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fang Li, M.D.</last_name>
    <phone>86-13910145882</phone>
    <email>nc_lifang@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Lung Cancer Center of Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinling Liu, Bachelor</last_name>
      <phone>86-10-87788495</phone>
      <email>liuxinling1985@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Fang Li, M.D.</last_name>
      <phone>86-13910145882</phone>
      <email>nc_lifang@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Xiangru Zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonz√°les-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.</citation>
    <PMID>16945766</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <last_update_submitted>March 8, 2010</last_update_submitted>
  <last_update_submitted_qc>March 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hejie</name_title>
    <organization>Cancer hospital and cancer institute, Chinese academy of medical sciences</organization>
  </responsible_party>
  <keyword>adjuvant therapy</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>vinorelbine</keyword>
  <keyword>cisplatin</keyword>
  <keyword>recombinant human endostatin(endostar)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

